Dergiler / Turkish Journal of Pediatrics / 2021 / Cilt: 63 - Sayı: 6

Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?

Sayfa
986–993
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Although we had a relatively small patient population, our findings indicate that PT might still be considered in selected patients particularly in countries where complement blocking therapies are difficult to reach due to their unavailability or costs that are not covered by the health care systems.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Atypical hemolytic uremic syndrome (aHUS) occurs due to defective regulation of the alternative complement pathway (ACP) on vascular endothelial cells.
📊
Temel Bulgular & Veri:The outcomes of seven genetically confirmed aHUS patients (2 girls, 5 males) were evaluated by means of clinical presentation, response to plasma therapy, course of the disease during the follow-up period and last status.
💡
Sonuç & Katkı:Although we had a relatively small patient population, our findings indicate that PT might still be considered in selected patients particularly in countries where complement blocking therapies are difficult to reach due to their unavailability or costs that are not covered by the health care systems.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background. Atypical hemolytic uremic syndrome (aHUS) occurs due to defective regulation of the alternative complement pathway (ACP) on vascular endothelial cells. Plasma based therapy (PT) was the mainstay of the treatment for aHUS for many years until the introduction of therapies targeting blockage of the complement system. The aim of this study was to evaluate patients with aHUS who had been treated with plasma based therapies alone. Methods. The outcomes of seven genetically confirmed aHUS patients (2 girls, 5 males) were evaluated by means of clinical presentation, response to plasma therapy, course of the disease during the follow-up period and last status. Results. The median age of the patients at admission was 6.7 years (IQR 0.7-7.8). Three patients received plasma exchange therapy and the other four patients were treated with plasma infusions. One patient was lost to follow-up after one year; the median duration of follow-up for other patients was 3.7 years (IQR 2.7-6.5). During the follow up, two patients from our historical records when complement blocking therapies had not been in clinical use yet in Turkey, underwent kidney transplantation. One transplant patient experienced an acute rejection episode without graft loss. The remaining five patients had a glomerular filtration rate of more than 90 ml/min./1.73 m 2 at the last visit. Conclusion. Although we had a relatively small patient population, our findings indicate that PT might still be considered in selected patients particularly in countries where complement blocking therapies are difficult to reach due to their unavailability or costs that are not covered by the health care systems.

🔖

Bu Makaleye Atıf Yap

ÖZLÜ, S. G., GÜLHAN, B., AYDOĞ, Ö., ATAYAR, E., DELİBAŞ, A., PARMAKSIZ, G., ÖZDOĞAN, E. B., ÇOMAK, E., TAŞDEMİR, M., ACAR, B., ÖZÇAKAR, Z. B., TOPALOĞLU, R., SÖYLEMEZOĞLU, O., ÖZALTIN, F. (2021). Could plasma based therapies still be considered in selected cases with atypical hemolytic uremic syndrome?. Turkish Journal of Pediatrics, Cilt: 63 - Sayı: 6, 986–993. https://ajindex.com/articles/411597

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Ruggenenti P, Noris M, Remuzzi G. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001
  2. https://doi.org/10.1046/j.1523- 1755.2001.060003831.x 2. Loirat C, Fakhouri F, Ariceta G, et al
  3. HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2016
  4. https://doi.org/10.1007/s00467-015-3076-8 3. Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol 2013
  5. https://doi.org/10.1016/j. semnephrol.2013.08.003 4. Ozaltin F, Li B, Rauhauser A, et al. DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN. J Am Soc Nephrol 2013
  6. https://doi.org/10.1681/ASN.2012090903 5. Bu F, Maga T, Meyer NC, et al. Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome. J Am Soc Nephrol 2014
  7. https://doi.org/10.1681/ ASN.2013050453 6. Ariceta G, Besbas N, Johnson S, et al
  8. European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea- negative hemolytic uremic syndrome. Pediatr Nephrol 2009
  9. https://doi.org/10.1007/ s00467-008-0964-1 7. Loirat C, Garnier A, Sellier-Leclerc AL, Kwon T. Plasmatherapy in atypical hemolytic uremic syndrome. Semin Thromb Hemost 2010
  10. https://doi.org/10.1055/s-0030-1262890 8. Besbas N, Gulhan B, Soylemezoglu O, et al. Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients. BMC Nephrol 2017
  11. https://doi.org/10.1186/s12882- 016-0420-6 9. Schwartz GJ, Muñoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009
  12. https://doi. org/10.1681/ASN.2008030287 10. Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J. Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 2000
  13. https://doi. org/10.1542/peds.105.6.1242 11. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis 2014
  14. https://doi. org/10.1053/j.ajkd.2014.01.41